Search
Researchers from The Kids Research Institute Australia will lead a world first trial to test the effectiveness of the drug interferon in stopping outbreaks of COVID-19 by reducing the infectiousness of people who contract the virus.
For families with a child with disability, this involves many extra care duties especially if their child has high and complex needs.
The rapidly developing coronavirus crisis is affecting our daily lives in unprecedented ways and brings with it uncertainty and fear.
The situation with COVID-19 is constantly evolving, and there is an extraordinary amount of information circulating which can be both overwhelming and difficult to navigate.
Schools are issuing restrictions around attendance after travel overseas due to coronavirus. Here's how to prepare your kids against the spread of infectious disease on their return to school.
Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Desiree Dr Jackie Lisa Susan Silva Davis Gibson Prescott MBBS, FRACP, MPH, PhD BSc (Hons), PGradDipHlthProm, PhD BA (Hons), MPsych, PhD MBBS BMedSci
To examine magnitude of the impact of the COVID-19 pandemic on inequalities in premature mortality in England by deprivation and ethnicity.
On 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.